FDA OKs LINZESS for Ages 2-5 FC, Expands Market to 2-17-Year-Olds
IRWD•The FDA approved LINZESS for pediatric patients ages 2-5 with FC, making it the only FDA-approved prescription therapy for 2-17-year-olds with the condition. A 12-week Phase 3 trial showed once-daily 72 mcg linaclotide increased spontaneous bowel movement frequency versus placebo and demonstrated a safety profile consistent with older groups.
1. Expanded FDA Indication
LINZESS received FDA approval for pediatric patients aged 2-5 with functional constipation, extending its indication downward from age 6. This makes LINZESS the only FDA-approved prescription therapy for children aged 2-17 with FC, filling a gap in treatment options for this age group.
2. Clinical Trial Results
The approval was supported by a 12-week, randomized, placebo-controlled Phase 3 trial evaluating once-daily 72 mcg linaclotide in patients aged 2-5 years. The study demonstrated a statistically significant increase in spontaneous bowel movement frequency versus placebo, and the safety profile matched data from adult and older pediatric trials.
3. Commercial Impact
Since its 2012 launch, LINZESS has treated over 5.5 million unique patients and leads the prescription market for IBS-C and adult CIC. The expanded pediatric indication leverages established formulary coverage and co-commercial partnerships, positioning the brand for additional uptake and revenue growth in the younger age cohort.
